2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.276

Change

-0.02 (-0.23)%

Market Cap

USD 1.14B

Volume

0.09M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.34 (+0.68%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.11 (+0.69%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.69%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.17 (+0.60%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.30 (+1.23%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.28%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+1.44 (+1.02%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.31 (+0.61%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.48 (+0.49%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.02 (+0.54%)

USD 80.38B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.70% 47% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.70% 47% F 51% F
Trailing 12 Months  
Capital Gain 20.19% 66% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.19% 66% D+ 68% D+
Trailing 5 Years  
Capital Gain 32.10% 60% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.10% 60% D- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 3.90% 44% F 45% F
Dividend Return 3.90% 43% F 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.95% 17% F 30% F
Risk Adjusted Return 18.63% 31% F 34% F
Market Capitalization 1.14B 80% B- 70% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.